Global Viral Vectors And Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids, Others), By Applications (Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research Applications), By Disease (Cancer, Genetic Disorders, Infectious Diseases, Others), By End-Use (Pharmaceutical and Biopharmaceutical Companies, Research Institutes) By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Industry Trends and Forecast to 2030.
Global Viral Vectors And Plasmid DNA Manufacturing Market
The Viral Vectors And Plasmid DNA Manufacturing market was valued at USD 5.33 billion in 2022 and is expected to reach USD 19.50 billion by 2030, with a CAGR of 17.26 % during the forecast period 2023-2030.
Plasmid DNA and viral vectors are methods for introducing genetic material into cells. Typically, viral vectors are used as gene therapy vectors. There are many different kinds of vectors, including herpes simplex virus and chimeric viral vectors. These include lentivirus, adenovirus, and adeno-associated virus (AAV). Additionally used as a vector in gene therapy and vaccination, plasmid DNA. There are many different viral vectors that are created using plasmid DNA as their basic material.
Drivers
The development of innovative gene therapies is strongly dependent on high-quality viral vectors and plasmid DNA, which is one of the key reasons driving the market. Additionally, advancements in manufacturing techniques have made it possible to generate viral vectors and plasmid DNA at higher volumes more successfully, while also lowering prices and raising general quality.
Impact of COVID-19
As viral vector-based vaccines may be produced and created reasonably fast with the use of the same building blocks, the ongoing COVID-19 pandemic has prompted investment in this area in quest of a vaccine. Examples of organizations that have created viral vector-based vaccinations include Johnson and Johnson/Janssen (J&J), AstraZeneca/University of Oxford, Gamaleya Research Institute, and CanSino Biologics.
Market Segmentation
Global Viral Vectors And Plasmid DNA Manufacturing Market is segmented into By Vector Type, By Applications, By Disease, By End-Use.
Based on the By Vector Type market is segmented into Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids, Others. Further market is segmented into By Applications market is segmented into Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research Applications. By Disease market is segmented into Cancer, Genetic Disorders, Infectious Diseases, Others. By End-Use market is segmented into Pharmaceutical and Biopharmaceutical Companies, Research Institutes.
Regional Analysis
Global Viral Vectors And Plasmid DNA Manufacturing Market is segmented into five main regions, namely, North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America dominates the Viral Vectors And Plasmid DNA Manufacturing market. The existence of a sizable number of centers and institutes involved in the R&D of advanced medicines is one of the key factors that has contributed to the huge share of this regional market. The federal agencies' investments in the region's cell therapy research base are expected to boost the market's expansion in North America.
Key Players.
Various key players are listed in this report such as Merck KGaA, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific, Catalent Inc., Wuxi Biologics, Takara Bio Inc., Waisman Biomanufacturing, Genezen laboratories, Batavia Biosciences, Miltenyi Biotec GmbH.
Market Taxonomy
By Vector Type
- Adenovirus
- Retrovirus
- Adeno-Associated Virus (AAV)
- Lentivirus
- Plasmids
- Others
- Antisense & RNAi Therapy
- Gene Therapy
- Cell Therapy
- Vaccinology
- Research Applications
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
- North America
- U.S.
- Canada
- Mexico
- Latin America
- Brazil
- Argentina
- Colombia
- Peru
- Chile
- Venezuela
- Rest of Latin America
- Europe
- Germany
- France
- UK
- Russia
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- New Zealand
- Singapore
- Malaysia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest Middle East & Africa
- What are the Key Opportunities in Global Viral Vectors And Plasmid DNA Manufacturing Market?
- What will be the growth rate from 2023 to 2030?
- Which segment/region will have highest growth?
- What are the factors that will impact/drive the Market?
- What is the competitive Landscape in the Industry?
- What is the role of key players in the value chain?
- 1 Introduction
- 1.1 Objective of the Study
- 1.2 Market definition
- 1.3 Market Scope
- 2 Research Methodology
- 2.1 Data Mining
- 2.2 Validation
- 2.3 Primary Interviews
- 2.4 List of Data Sources
- 3 Executive Summary
- 4 Global Viral Vectors And Plasmid DNA Manufacturing Market Outlook
- 4.1 Overview
- 4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
- 4.2.4Cumulative Impact due to recent Energy Crisis
- 4.2.5 Cumulative Impact due to nearing Economic Downturn
- 4.2.6 Post Covid-19 World supply and Demand Condition
- 4.2.7 Cumulative Impact of Russia Ukraine Conflict
- 4.3 Porters Five Force Model
- 4.4 Value Chain Analysis
- 5 Global Viral Vectors And Plasmid DNA Manufacturing Market, By Vector Type
- 5.1 Y-o-Y Growth Comparison, By Vector Type
- 5.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
- 5.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Vector Type
- 5.3.1 Adenovirus
- 5.3.2 Retrovirus
- 5.3.3 Adeno-Associated Virus (AAV)
- 5.3.4 Lentivirus
- 5.3.5 Plasmids
- 5.3.5 Others
- 6 Global Viral Vectors And Plasmid DNA Manufacturing Market, By Applications
- 6.1 Y-o-Y Growth Comparison, By Applications
- 6.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Applications
- 6.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
- 6.3.1 Antisense & RNAi Therapy
- 6.3.2 Gene Therapy
- 6.3.3 Cell Therapy
- 6.3.4 Vaccinology
- 6.3.5 Research Applications
- 7 Global Viral Vectors And Plasmid DNA Manufacturing Market, By Disease
- 7.1 Y-o-Y Growth Comparison, By Disease
- 7.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Disease
- 7.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
- 7.3.1 Cancer
- 7.3.2 Genetic Disorders
- 7.3.3 Infectious Diseases
- 7.3.4 Others
- 8 Global Viral Vectors And Plasmid DNA Manufacturing Market, By End-Use
- 8.1 Y-O-Y Growth Comparison, By End-Use
- 8.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By End-Use
- 8.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
- 8.3.1 Pharmaceutical and Biopharmaceutical Companies
- 8.3.2 Research Institutes
- 9 Global Viral Vectors And Plasmid DNA Manufacturing Market, By Region
- 9.1 Global Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Region
- 9.2 Global Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Region
- 9.3 Global Viral Vectors And Plasmid DNA Manufacturing Market Trends and Forecast, By Region
- 10 North America Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
- 10.1 Introduction
- 10.2 North America Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
- 10.3 North America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
- 10.4 North America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
- 10.5 North America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
- 10.6 North America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
- 10.6.1 U.S.
- 10.6.1.1. Market Size and Forecast, By Vector Type
- 10.6.1.2 Market Size and Forecast, By Applications
- 10.6.1.3. Market Size and Forecast, By Disease
- 10.6.1.4 Market Size and Forecast, By End-Use
- 10.6.2 Canada
- 10.6.2.1. Market Size and Forecast, By Vector Type
- 10.6.2.2 Market Size and Forecast, By Applications
- 10.6.2.3. Market Size and Forecast, By Disease
- 10.6.2.4 Market Size and Forecast, By End-Use
- 10.6.3 Mexico
- 10.6.3.1. Market Size and Forecast, By Vector Type
- 10.6.3.2 Market Size and Forecast, By Applications
- 10.6.3.3. Market Size and Forecast, By Disease
- 10.6.3.4 Market Size and Forecast
- 11 Europe Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
- 11.1 Introduction
- 11.2 Europe Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
- 11.3 Europe Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
- 11.4 Europe Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
- 11.5 Europe Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
- 11.6 Europe Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
- 11.6.1 Germany
- 11.6.1.1. Market Size and Forecast, By Vector Type
- 11.6.1.2 Market Size and Forecast, By Applications
- 11.6.1.3. Market Size and Forecast, By Disease
- 11.6.1.4 Market Size and Forecast By End-Use
- 11.6.2 France
- 11.6.2.1. Market Size and Forecast, By Vector Type
- 11.6.2.2 Market Size and Forecast, By Applications
- 11.6.2.3. Market Size and Forecast, By Disease
- 11.6.2.4 Market Size and Forecast, By End-Use
- 11.6.3 UK
- 11.6.3.1. Market Size and Forecast, By Vector Type
- 11.6.3.2 Market Size and Forecast, By Applications
- 11.6.3.3. Market Size and Forecast, By Disease
- 11.6.3.4. Market Size and Forecast, By End-Use
- 11.6.4. Russia
- 11.6.4.1. Market Size and Forecast, By Vector Type
- 11.6.4.2 Market Size and Forecast, By Applications
- 11.6.4.3. Market Size and Forecast, By Disease
- 11.6.4.4 Market Size and Forecast, By End-Use
- 11.6.5. Italy
- 11.6.5.1. Market Size and Forecast, By Vector Type
- 11.6.5.2 Market Size and Forecast, By Applications
- 11.6.5.3. Market Size and Forecast, By Disease
- 11.6.5.4 Market Size and Forecast, By End-Use
- 11.6.6. Spain
- 11.6.6.1. Market Size and Forecast, By Vector Type
- 11.6.6.2 Market Size and Forecast, By Applications
- 11.6.6.3. Market Size and Forecast, By Disease
- 11.6.6.4 Market Size and Forecast By End-Use
- 11.6.7. Rest of Europe
- 11.6.7.1. Market Size and Forecast, By Vector Type
- 11.6.7.2 Market Size and Forecast, By Applications
- 11.6.7.3. Market Size and Forecast, By Disease
- 11.6.7.4 Market Size and Forecast, By End-Use
- 12 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
- 12.1 Introduction
- 12.2 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
- 12.3 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
- 12.4 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
- 12.5 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
- 12.6 Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
- 12.6.1 China
- 12.6.1.1. Market Size and Forecast, By Vector Type
- 12.6.1.2 Market Size and Forecast, By Applications
- 12.6.1.3. Market Size and Forecast, By Disease
- 12.6.1.4 Market Size and Forecast, By End-Use
- 12.6.2 Japan
- 12.6.2.1. Market Size and Forecast, By Vector Type
- 12.6.2.2 Market Size and Forecast, By Applications
- 12.6.2.3. Market Size and Forecast, By Disease
- 12.6.2.4 Market Size and Forecast, By End-Use
- 12.6.3 India
- 12.6.3.1. Market Size and Forecast, By Vector Type
- 12.6.3.2 Market Size and Forecast, By Applications
- 12.6.3.3. Market Size and Forecast, By Disease
- 12.6.3.4 Market Size and Forecast By End-Use ,
- 12.6.4. South Korea
- 12.6.4.1. Market Size and Forecast, By Vector Type
- 12.6.4.2 Market Size and Forecast, By Applications
- 12.6.4.3. Market Size and Forecast, By Disease
- 12.6.4.4 Market Size and Forecast, By End-Use
- 12.6.5. Australia
- 12.6.5.1. Market Size and Forecast, By Vector Type
- 12.6.5.2 Market Size and Forecast, By Applications
- 12.6.5.3. Market Size and Forecast, By Disease
- 12.6.5.4 Market Size and Forecast, By End-Use
- 12.6.6. New Zealand
- 12.6.6.1. Market Size and Forecast, By Vector Type
- 12.6.6.2 Market Size and Forecast, By Applications
- 12.6.6.3. Market Size and Forecast, By Disease
- 12.6.6.4 Market Size and Forecast, By End-Use
- 12.6.7. Singapore
- 12.6.7.1. Market Size and Forecast, By Vector Type
- 12.6.7.2 Market Size and Forecast, By Applications
- 12.6.7.3. Market Size and Forecast, By Disease
- 12.6.7.4 Market Size and Forecast, By End-Use
- 12.6.8. Malaysia
- 12.6.8.1. Market Size and Forecast, By Vector Type
- 12.6.8.2 Market Size and Forecast, By Applications
- 12.6.8.3. Market Size and Forecast, By Disease
- 12.6.8.4 Market Size and Forecast, By End-Use
- 12.6.9. Rest of Asia
- 12.6.9.1. Market Size and Forecast, By Vector Type
- 12.6.9.2 Market Size and Forecast, By Applications
- 12.6.9.3. Market Size and Forecast, By Disease
- 12.6.9.4 Market Size and Forecast, By End-Use
- 13 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
- 13.1 Introduction
- 13.2 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
- 13.3 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
- 13.4 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
- 13.5 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
- 13.6 Latin America Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
- 13.6.1 Brazil
- 13.6.1.1. Market Size and Forecast, By Vector Type
- 13.6.1.2 Market Size and Forecast, By Applications
- 13.6.1.3. Market Size and Forecast, By Disease
- 13.6.1.4 Market Size and Forecast, By End-Use
- 13.6.2 Argentina
- 13.6.2.1. Market Size and Forecast, By Vector Type
- 13.6.2.2 Market Size and Forecast, By Applications
- 13.6.2.3. Market Size and Forecast, By Disease
- 13.6.2.4 Market Size and Forecast, By End-Use
- 13.6.3. Colombia
- 13.6.3.1. Market Size and Forecast, By Vector Type
- 13.6.3.2 Market Size and Forecast, By Applications
- 13.6.3.3. Market Size and Forecast, By Disease
- 13.6.3.4 Market Size and Forecast, By End-Use
- 13.6.4. Peru
- 13.6.4.1. Market Size and Forecast, By Vector Type
- 13.6.4.2 Market Size and Forecast, By Applications
- 13.6.4.3. Market Size and Forecast, By Disease
- 13.6.4 Market Size and Forecast, By End-Use
- 13.6.5. Chile
- 13.6.5.1. Market Size and Forecast, By Vector Type
- 13.6.5.2 Market Size and Forecast, By Applications
- 13.6.5.3. Market Size and Forecast, By Disease
- 13.6.5.4 Market Size and Forecast, By End-Use
- 13.6.6. Venezuela
- 13.6.6.1. Market Size and Forecast, By Vector Type
- 13.6.6.2 Market Size and Forecast, By Applications
- 13.6.6.3. Market Size and Forecast, By Disease
- 13.6.6.4 Market Size and Forecast, By End-Use
- 13.6.7. rest of Latin America
- 13.6.7.1. Market Size and Forecast, By Vector Type
- 13.6.7.2 Market Size and Forecast, By Applications
- 13.6.7.3. Market Size and Forecast, By Disease
- 13.6.7.4 Market Size and Forecast, By End-Use
- 14 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Analysis and Forecast (2023-2030)
- 14.1 Introduction
- 14.2 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Share Analysis, By Vector Type
- 14.3 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Applications
- 14.4 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Disease
- 14.5 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By End-Use
- 14.6 Middle East Viral Vectors And Plasmid DNA Manufacturing Market Size and Forecast, By Country
- 14.6.1. Saudi Arabia
- 14.6.1.1. Market Size and Forecast, By Vector Type
- 14.6.1.2 Market Size and Forecast, By Applications
- 14.6.1.3. Market Size and Forecast, By Disease
- 14.6.1.4 Market Size and Forecast, By End-Use
- 14.6.2 UAE
- 14.6.2.1. Market Size and Forecast, By Vector Type
- 14.6.2.2 Market Size and Forecast, By Applications
- 14.6.2.3. Market Size and Forecast, By Disease
- 14.6.2.4 Market Size and Forecast, By End-Use
- 14.6.3 Egypt
- 14.6.3.1. Market Size and Forecast, By Vector Type
- 14.6.3.2 Market Size and Forecast, By Applications
- 14.6.3.3. Market Size and Forecast, By Disease
- 14.6.3.4 Market Size and Forecast, By End-Use
- 14.6.4 Kuwait
- 14.6.4.1. Market Size and Forecast, By Vector Type
- 14.6.4.2 Market Size and Forecast, By Applications
- 14.6.4.3. Market Size and Forecast, By Disease
- 14.6.4.4 Market Size and Forecast, By End-Use
- 14.6.5 South Africa
- 14.6.5.1. Market Size and Forecast, By Vector Type
- 14.6.5.2 Market Size and Forecast, By Applications
- 14.6.5.3. Market Size and Forecast, By Disease
- 14.6.5.4 Market Size and Forecast, By End-Use
- 14.6.5 Rest of Middle East & Africa
- 14.6.6.1. Market Size and Forecast, By Vector Type
- 14.6.6.2 Market Size and Forecast, By Applications
- 14.6.6.3. Market Size and Forecast, By Disease
- 14.6.6.3 Market Size and Forecast, By End-Use
- 15 Competitive Analysis
- 15.1 Competition Dashboard
- 15.2 Market share Analysis of Top Vendors
- 15.3 Key Development Strategies
- 16 Company Profiles
- 16.1 Merck KGaA
- 16.1.1 Overview
- 16.1.2 Offerings
- 16.1.3 Key Financials
- 16.1.4 Business Segment & Geographic Overview
- 16.1.5 Key Market Developments
- 16.1.6 Key Strategies
- 16.2 FUJIFILM Diosynth Biotechnologies
- 16.2.1 Overview
- 16.2.2 Offerings
- 16.2.3 Key Financials
- 16.2.4 Business Segment & Geographic Overview
- 16.2.5 Key Market Developments
- 16.2.6 Key Strategies
- 16.3. Thermo Fisher Scientific
- 16.3.1 Overview
- 16.3.2 Offerings
- 16.3.3 Key Financials
- 16.3.4 Business Segment & Geographic Overview
- 16.3.5 Key Market Developments
- 16.3.6 Key Strategies
- 16.4. Catalent Inc.
- 16.4.1 Overview
- 16.4.2 Offerings
- 16.4.3 Key Financials
- 16.4.4 Business Segment & Geographic Overview
- 16.4.5 Key Market Developments
- 16.4.6 Key Strategies
- 16.5 Wuxi Biologics
- 16.5.1 Overview
- 16.5.2 Offerings
- 16.5.3 Key Financials
- 16.5.4 Business Segment & Geographic Overview
- 16.5.5 Key Market Developments
- 16.5.6 Key Strategies
- 16.6 Takara Bio Inc.
- 16.6.1 Overview
- 16.6.2 Offerings
- 16.6.3 Key Financials
- 16.6.4 Business Segment & Geographic Overview
- 16.6.5 Key Market Developments
- 16.6.6 Key Strategies
- 16.7 Waisman Biomanufacturing
- 16.7.1 Overview
- 16.7.2 Offerings
- 16.7.3 Key Financials
- 16.7.4 Business Segment & Geographic Overview
- 16.7.5 Key Market Developments
- 16.7.6 Key Strategies
- 16.8 Genezen laboratories
- 16.8.1 Overview
- 16.8.2 Offerings
- 16.8.3 Key Financials
- 16.8.4 Business Segment & Geographic Overview
- 16.8.5 Key Market Developments
- 16.8.6 Key Strategies
- 16.9 Batavia Biosciences
- 16.9.1 Overview
- 16.9.2 Offerings
- 16.9.3 Key Financials
- 16.9.4 Business Segment & Geographic Overview
- 16.9.5 Key Market Developments
- 16.9.6 Key Strategies
- 16.10 Miltenyi Biotec GmbH
- 16.10.1 Overview
- 16.10.2 Offerings
- 16.10.3 Key Financials
- 16.10.4 Business Segment & Geographic Overview
- 16.10.5 Key Market Developments
- 16.10.6 Key Strategies
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook